logo-loader
HealthMedical technology & services
viewLombard Medical Technologies

Lombard Medical Technologies gets US approval for breakthrough device

Lombard Medical Technologies has achieved what many hundreds of companies strive for each year but fail to deliver – US Food & Drug Administration approval for a device or a drug.

microscope350_511dea18715c2.jpg

Lombard Medical Technologies (LON:LMT) has achieved what many hundreds of companies strive for each year but fail to deliver: US Food & Drug Administration (FDA) approval for a device or a drug.

In this case it has received the regulator sign-off from the one of the world’s most powerful regulatory bodies for Aorfix, a flexible stent graft used to treat abdominal aortic aneurysms (ruptures to the main artery).

The FDA green light allows the stent to be sold into the world’s largest market for medical devices and drugs.

Independent research suggests the US the market for the repair of abdominal aortic aneurysms is worth over US$600 million a year.

The approval triggers receipt of the £14.1mln second tranche of the two tranche placing and subscription announced by the company on April 20, 2011.

The cash will be used to launch Aorfix in the States via the company's own direct sales force.

Lombard chief executive Simon Hubbert said: "FDA approval of Aorfix is a major milestone for the company and sets the stage for the next chapter in the company's growth.

“I would like to thank all of our employees, investigators and clinical advisors for their support and hard work, without which development and approval of Aorfix would not have been possible.”


 

Quick facts: Lombard Medical Technologies

Price: 0 0

AIM:LMT
Market: AIM
Market Cap: £0.00
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Group Eleven Resources finds a new investor in mining giant...

Group Eleven Resources (CVE: ZNG) CEO Bart Jaworski joined Steve Darling from Proactive Vancouver on Skype to discuss the news Glencore (LON: GLEN) has entered a shareholder agreement on Group Eleven’s Zinc Exploration in Ireland. Jaworski telling Proactive how the deal works and what it...

1 day, 18 hours ago

2 min read